Second Sight Medical Products Inc (NASDAQ:EYES) Director Gregg Williams purchased 4,000,000 shares of the firm’s stock in a transaction that occurred on Friday, April 7th. The shares were bought at an average price of $1.00 per share, for a total transaction of $4,000,000.00. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Shares of Second Sight Medical Products Inc (NASDAQ:EYES) opened at 1.16 on Thursday. Second Sight Medical Products Inc has a 1-year low of $1.06 and a 1-year high of $6.05. The firm has a 50-day moving average price of $1.36 and a 200-day moving average price of $1.99. The stock’s market cap is $65.38 million.
Second Sight Medical Products (NASDAQ:EYES) last announced its earnings results on Thursday, March 9th. The medical device company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by $0.07. The company had revenue of $0.72 million for the quarter, compared to analyst estimates of $1.76 million. Second Sight Medical Products had a negative net margin of 502.22% and a negative return on equity of 121.31%. Second Sight Medical Products’s quarterly revenue was down 70.2% compared to the same quarter last year. During the same quarter last year, the company posted ($0.13) EPS. Equities analysts forecast that Second Sight Medical Products Inc will post ($0.54) EPS for the current year.
TRADEMARK VIOLATION NOTICE: “Second Sight Medical Products Inc (EYES) Director Buys $4,000,000.00 in Stock” was published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this piece on another website, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.chaffeybreeze.com/2017/04/13/second-sight-medical-products-inc-eyes-director-buys-4000000-00-in-stock.html.
Separately, HC Wainwright set a $16.00 price target on Second Sight Medical Products and gave the company a “buy” rating in a report on Sunday, December 25th.
A number of large investors have recently made changes to their positions in EYES. Versant Venture Management LLC bought a new stake in shares of Second Sight Medical Products during the first quarter worth approximately $5,436,000. Van Den Berg Management I Inc. boosted its stake in shares of Second Sight Medical Products by 15.5% in the fourth quarter. Van Den Berg Management I Inc. now owns 191,577 shares of the medical device company’s stock worth $377,000 after buying an additional 25,677 shares during the period. Finally, Psagot Investment House Ltd. boosted its stake in shares of Second Sight Medical Products by 88.3% in the fourth quarter. Psagot Investment House Ltd. now owns 104,230 shares of the medical device company’s stock worth $205,000 after buying an additional 48,868 shares during the period. Hedge funds and other institutional investors own 6.57% of the company’s stock.
Second Sight Medical Products Company Profile
Second Sight Medical Products, Inc is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight.
Receive News & Ratings for Second Sight Medical Products Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Second Sight Medical Products Inc and related companies with MarketBeat.com's FREE daily email newsletter.